Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer

February 11, 2011 updated by: AGO Study Group
The purpose of this study is to validate a score developed by the AGO-OVAR for complete resection of the tumor

Study Overview

Status

Completed

Conditions

Detailed Description

The multicentre retrospective study AGO-DESKTOP OVAR 1 investigated in a multicentre-setting the question of prognostic factors for a successful (i.e. complete) debulking for recurrence. That way, a hypothesis for a score with 3 factors could be developed:

  • PS ECOG = 0
  • tumor-free after primary surgery (if unknown: FIGO I/II)
  • Ascites < 500 ml.

The goal of this study is to evaluate in a prospective multicentre setting, to what extent this retrospectively defined AGO-score has predictive validity. The criterion aimed at is therefore the rate of complete tumor resections if the three score characteristics are present in invasive epithelial platinum-sensitive ovarian-, fallopian tube- or primary peritoneal cancer. This study will be the second in a series of three: (1) hypothesis building for a potential predictive score for resectability, (2) prospective confirmation of the AGO-score, and (3) application of the AGO-score as inclusion criteria for eligible patients in whom a formal comparison of the role of secondary debulking of relapsed ovarian cancer could be performed.

Study Type

Observational

Enrollment (Actual)

122

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Innsbruck, Austria, 6020
        • Universitätskliniken LKH Innsbruck
  • Belgium
      • Leuven, Belgium, 3000
        • University Hospitals Leuven
  • Germany
      • Frankfurt, Germany, 60596
        • Klinikum der Johann Wolfgang Goethe Universitat
      • Freiburg, Germany, 79106
        • Universitätsklinikum Freiburg
      • Karlsruhe, Germany, 76135
        • St. Vincentius Kliniken gAG
      • Landshut, Germany, 84034
        • Klinikum Landshut gGmbH
      • Lüneburg, Germany, 21339
        • Städtisches Krankenhaus Lüneburg
      • Neumarkt, Germany, 92318
        • Klinikum Neumarkt
      • Wiesbaden, Germany, 65199
        • HSK, Dr. Horst Schmidt Klinik
      • Wolfsburg, Germany, 38440
        • Klinikum der Stadt Wolfsburg
  • Italy
      • Campobasso, Italy, 86100
        • Catholic University Of Sacred Heart
      • Milan, Italy, 20141
        • European Institute of Oncology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage who have relapsed after a tumor-free interval of at least 6 months after completion of first-line therapy.

Description

Inclusion Criteria:

  • Patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage who have relapsed after a tumor-free interval of at least 6 months after completion of first-line therapy. The same interval applies to patients with second relapse who are enrolled after completed platinum-containing re-induction therapy.
  • Women aged > 18 years
  • Patients who have given their signed and written informed consent to data transmission and -processing

Exclusion Criteria:

  • Patients with non-epithelial tumors as well as borderline tumors
  • Patients who undergo second-look surgery or completion surgery after end of chemotherapy or during the interval
  • Only for the study collective: patients with second malignancies who have been treated by laparotomy, as well as other neoplasias, if the treatment could interfere with the treatment of relapsed ovarian cancer
  • Patients with a third recurrence
  • Patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former platinum-containing therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AGO Study Group

Collaborators

Arbeitsgemeinschaft Gynaekologische Onkologie Austria
MITO

Investigators

  • Principal Investigator: Philipp Harter, Dr., Dr. Horst Schmidt Klinik Wiesbaden
  • Study Chair: Annette Hasenburg, PD Dr., Universitäts-Frauenklinik Freiburg
  • Study Director: Andreas du Bois, Prof. Dr., Dr. Horst Schmidt Klinik Wiesbaden

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2006

Primary Completion (Actual)

July 1, 2008

Study Completion (Actual)

October 1, 2009

Study Registration Dates

First Submitted

August 23, 2006

First Submitted That Met QC Criteria

August 23, 2006

First Posted (Estimate)

August 24, 2006

Study Record Updates

Last Update Posted (Estimate)

February 15, 2011

Last Update Submitted That Met QC Criteria

February 11, 2011

Last Verified

February 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AGO-OVAR OP.2
  • AGO DESKTOP OVAR II

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ovarian Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe